Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2007. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported in this filing. The only reported activity is an increase in Ordinary Share ADR holdings by specific individuals following the re-investment of dividends paid on October 11, 2007.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly details compliance with Disclosure and Transparency Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Re-investment of dividends into Ordinary Share ADRs.
- Transaction Price: $52.41 per ADR.
- Dividend Date: October 11, 2007.
- Notification Date: October 16, 2007.
- Individuals Notified: Dr. JP Garnier (711.07 ADRs), Mr. D J Phelan (152.37 ADRs), and Mr. D M Stout (73.79 ADRs).